Market Overview

UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight; Overhang Removed

Share:
Related ALNY
Alnylam Initiates Phase 3 Open Label Extension Study with Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR Amyloidosis)
5 Biotech Stocks On Deck With The FDA
Alnylam initiates Phase 1/2 ALN-AAT trial in liver disease (Seeking Alpha)

Piper Jaffray raised its rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and increased its price target from $19 to $25.

Piper Jaffray noted, "With the Tekmira litigation behind them, Alnylam can now focus on RNAi clinical progress and partnerships in 2013. Specifically, we look forward to Phase II ALN-TTR02 data this summer to prepare the company for pivotal studies by year-end. We also expect Alnylam to file INDs on sub-cutaneous formulations of ALN-TTR02 and ALN-AT3, an innovative hemophilia therapy. We also look for Alnylam to continue to partner its RNAi therapeutic pipeline, most importantly ALN-PCS to lower cholesterol."

Alnylam Pharmaceuticals closed at $17.99 on Tuesday.

Latest Ratings for ALNY

DateFirmActionFromTo
Jun 2015Piper JaffrayReiteratesOutperform
Mar 2015Janney CapitalInitiates Coverage on
Mar 2015BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALNY)

Get Benzinga's Newsletters